Trial Profile
Dose optimization of Certolizumab Pegol in patients with moderate to severe Crohn's disease (CD).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- 18 Dec 2015 New trial record